C4X to quit stock market and seek venture funding for drug discovery
Languishing share price and high cost of regulatory burden of AIM listing makes decision a no-brainer
Source: thebusinessdesk.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Receptor Antagonist Programme. Real-time updates on events, politics, business and more.